سعر نوروكارمينا 28 قرص 0.02 مجم/3 مجم 2025

Ethinylestradiol 0.02 mg / drospirenone 3 mg combined oral contraceptive, pack of 28 tablets (Laboratoires Léon / Amriya, Egypt).

• Prevention of pregnancy (oral contraception)Population: Females of reproductive potentialDailyMed (U.S. National Library of Medicine)

• Reported adverse reactions include headache, depressive mood, migraine, nausea, menstrual disorders and intermenstrual bleeding, breast pain/tenderness, vaginal discharge and vulvovaginal candidiasis; serious risks include venous and arterial thromboembolism.General active-ingredient information · electronic medicines compendium (eMC), MHRA-authorised SmPC

• Presence or risk of venous or arterial thromboembolism (current or past VTE, hereditary/acquired predisposition, major surgery with prolonged immobilisation, MI, stroke/TIA, migraine with focal neurological symptoms, diabetes with vascular symptoms, severe hypertension, severe dyslipoproteinaemia); severe hepatic disease until liver function normalises; liver tumours; severe renal insufficiency or acute renal failure; known or suspected sex-steroid-influenced malignancies; undiagnosed vaginal bleeding; hypersensitivity. Contraindicated with ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.General active-ingredient information · electronic medicines compendium (eMC), MHRA-authorised SmPC

• Boxed warning: cigarette smoking increases the risk of serious cardiovascular events from COC use, especially in women over 35; COCs should not be used by women over 35 who smoke.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Increased risk of venous thromboembolism (VTE) with CHCs; consider the woman's individual risk factors and how the VTE risk with drospirenone-containing products compares with other CHCs before prescribing. Depressed mood is a recognised effect; advise contact with a doctor if it occurs.General active-ingredient information · electronic medicines compendium (eMC), MHRA-authorised SmPC

• Enzyme inducers (e.g. barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, ritonavir, nevirapine, efavirenz, St John's wort)Hepatic enzyme inducers can increase clearance of sex hormones and may cause breakthrough bleeding and/or contraceptive failure.electronic medicines compendium (eMC), MHRA-authorised SmPC
• Potassium-sparing diuretics, aldosterone antagonists and other drugs raising potassiumDrospirenone has antimineralocorticoid (potassium-sparing) activity; consider checking serum potassium in the first cycle, especially with renal impairment.electronic medicines compendium (eMC), MHRA-authorised SmPC

• Not indicated during pregnancy; if pregnancy occurs during use, stop immediately. Epidemiological studies have shown neither an increased risk of birth defects with COC use before pregnancy nor teratogenic effects with inadvertent use in pregnancy.General active-ingredient information · electronic medicines compendium (eMC), MHRA-authorised SmPC
• COCs may reduce the quantity and change the composition of breast milk; use is generally not recommended until the breastfeeding mother has completely weaned her child. Small amounts of the steroids may pass into milk.General active-ingredient information · electronic medicines compendium (eMC), MHRA-authorised SmPC

• Ethinylestradiol: As part of an estrogen-progestogen combination: inhibits ovulation by suppressing the mid-cycle LH surge, thickens cervical mucus and makes the endometrium unreceptive to implantation.
• Drospirenone: Binds progesterone receptors; antimineralocorticoid and antiandrogenic activity.